US EditionSpanish Flavor in the Last Big Breakthrough Against Lung Cancer
Summary by www.larazon.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
A study conducted by Hospital 12 de Octubre, in Madrid, with a combination of two drugs, the immunotherapy atezolizumab and the transcription inhibitor, lurbinectedin, developed by the Spanish company PharmaMar, has shown significant improvement in the time a patient lives from the beginning of treatment and the time that passes without the disease advancing in patients with advanced small cell lung cancer (SCLC) and also reduced the risk of dis…
·Spain
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
